Supplementing punicalagin reduces oxidative stress markers and restores angiogenic balance in a rat model of pregnancy-induced hypertension

Yujue Wang1,*, Mengwei Huang2,*, Xiaofeng Yang3, Zhongmei Yang1, Lingling Li1, and Jie Mei1

1Department of Obstetrics and Gynecology, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, Chengdu City, Sichuan 610072, 2Department of Obstetrics and Gynecology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646099, China

ARTICLE INFO
Received December 2, 2017
Revised January 8, 2018
Accepted January 27, 2018
*Correspondence
Jie Mei
E-mail: MEveliadraf@yahoo.com

Key Words
Angiogenic balance
Gestational hypertension
Oxidative stress
Pre-eclampsia
Punicalagin

These authors contributed equally to this work.

ABSTRACT Pre-eclampsia (PE) is a pregnancy disorder that is characterised by severe hypertension and increased risks of foetal and maternal mortality. The aetiology of PE not completely understood; however, maternal nutrition and oxidative stress play important roles in the development of hypertension. The treatment options for PE are currently limited to anti-hypertensive drugs. Punicalagin, a polyphenol present in pomegranate juice, has a range of bioactive properties. The effects of supplementation with punicalagin on angiogenesis and oxidative stress in pregnant rats with induced hypertension were investigated. The pregnant rats were randomly divided into five experimental groups (n=12 per group). Hypertension was induced using an oral dose of NG-nitro-L-arginine methyl ester (L-NAME, 50 mg/kg/day) on days 14-19 of pregnancy. Punicalagin (25, 50 or 100 mg/kg) was given orally on days 14-21 of pregnancy. Punicalagin treatment at the tested doses significantly reduced diastolic, systolic, and mean arterial blood pressure in L-NAME treated rats from day 14. Punicalagin also restored angiogenic balance by increasing the expression of vascular endothelial growth factor and downregulating vascular endothelial growth factor receptor-1/fms-like tyrosine kinase-1. Punicalagin significantly increased the placental nitric oxide levels as compared to PE group. The increased levels of oxidative stress in rats with PE were markedly decreased by treatment with punicalagin. Punicalagin at the tested doses markedly (p<0.05) enhanced the placental antioxidant capacity in L-NAME-treated rats. The raised catalase activity observed following L-NAME induction was significantly (p<0.05) and restored to normal activity levels in punicalagin treatment. Further, 100 mg dose of punicalagin exhibited higher protective effects as compared to lower doses of 25 and 50 mg. This study shows that supplementation with punicalagin decreased blood pressure and oxidative stress and restored angiogenic balance in pregnant rats with induced PE.

INTRODUCTION

Pre-eclampsia (PE) is clinical condition that occurs during pregnancy and is generally associated with an abnormal placenta [1,2]. PE is characterised by elevated blood pressure and proteinuria. It is one of the main causes of maternal and foetal mortality and affects women only after 20 weeks of gestation [3-5]. In developed countries, PE is responsible for approximately 15% of preterm deliveries and 18% of maternal deaths [6-8]. Despite extensive research, the underlying pathogenesis of pregnancy-induced hypertension (PIH) is not completely understood, and this limits the available treatment options [9].

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © Korean J Physiol Pharmacol, pISSN 1226-4512, eISSN 2093-3827

Author contributions: Y.W. and M.H. had equally contributed to this work and performed all activities relating to this study. X.Y., Z.Y., L.L. and J.M. coordinated the study and performed experiments and analysed the data.
Recent research has demonstrated that oxidative stress plays a critical role in the development of PE [10-13] and that increased levels of anti-angiogenic factors are significantly associated with PIH [14-16]. This angiogenic imbalance is characterised by alterations in the ratios of pro-angiogenic factors, including vascular endothelial growth factor (VEGF) and anti-angiogenic factors, including fms-like tyrosine kinase-1 (Flt-1) and soluble VEGF receptor-1 (VEGFR-1). Remodelling of the maternal uterine vasculature occurs in patients with PE, and placental ischaemia and hypoxic conditions contribute significantly to angiogenic imbalance [17,18]. The disrupted angiogenic balance and altered regulation of a variety of factors lead to inflammatory responses and oxidative stress, which eventually result in endothelial dysfunction and hypertension [19-21]. Experimental studies using rodent models of PE have focused on restoring angiogenic balance, which can reduce hypertension [14,15,22,23]. As a result, identifying and developing therapeutic strategies that can reduce maternal inflammation, oxidative stress and endothelial dysfunction are extremely important for treating PE.

Pomegranate (Punica granatum) fruits are widely consumed and have antioxidant, anti-hyperglycaemic, hepatoprotective, cardioprotective and anti-epileptic effects [24-26]. Pomegranate extracts can inhibit the proliferation of cancer cells [27,28]. Pomegranate juice contains polyphenols including gallotannins, ellagitannins and flavonoids [29], which can improve cardiovascular activity, attenuate hypoxia-induced apoptosis, reduce inflammation and restore endothelial-cell function in vitro [30,31]. Here we investigated the effects of punicalagin, the most abundant ellagitannin in pomegranate juice, on oxidative stress and angiogenic balance in rats with experimentally induced PE.

**METHODS**

**Study animals**

A total of 20 male (weight, 300-325 g) and 60 female (weight, 200-250 g) Sprague-Dawley rats were monitored in sterile cages under laboratory conditions (12 h day/night cycle; 22-23°C; humidity, 55-60%). The study was conducted in compliance with international guidelines for the study of laboratory animals and the national animal welfare laws of China. The experimental protocols were approved by the Southwest Medical University Animal Care Board [32].

Female rats in the same ovulation cycle stage were randomly separated into six sets (n=10 per group), where the set ratio was 3:1 females/males. The animals were bred for 3 days, and female rats were then inspected for the presence of a vaginal plug, which indicated successful copulation. The rats with vaginal plugs were separated and labelled ‘day 0 of pregnancy.’

**Reagents and antibodies**

Punicalagin and NG-nitro-L-arginine methyl ester (L-NAME) were obtained from Sigma-Aldrich (St. Louis, MO, USA). The buffers used for western blotting analysis were procured from the Beyotime Institute of Biotechnology (Beijing, China). The antibodies raised against VEGF and VEGFR-1/Flt-1 were from Cell Signaling Technology (Danvers, MA, USA), and the horseradish peroxidase (HRP)-labelled IgG secondary antibodies and β-actin were from Santa Cruz Biotechnology (Dallas, TX, USA). The remaining reagents used in this study were from Sigma-Aldrich unless otherwise stated.

**Trial design**

The animals were randomly separated into five groups of 12 rats. Hypertension was induced in pregnant rats using the nitric oxide synthase (NOS) inhibitor L-NAME [33,34]. Each group of rats received 50 mg/kg/day of L-NAME by gavage on days 14-19 of pregnancy. The treatment group animals additionally received 25, 50 or 100 mg/kg of punicalagin every day by oral gavage on days 14-21 of pregnancy. During gestation, the pregnant rats were kept in an animal house under standard conditions.

On day 21 of gestation, the rats were anaesthetised using a mixture of intramuscular ketamine (90-100 mg/kg) and xylazine (10 mg/kg), and hysterotomies were performed. Both live and dead foetuses were collected and weighed. Placentas were also collected, and the rats were sacrificed by administration of intraperitoneal phenobarbital (100 mg/kg) after the surgery was completed.

**Blood pressure measurements**

Blood pressure was recorded on days 1, 7, 14, 16, 18 and 20 using the CODA 6 BP system (Kent Scientific, Torrington, CT, USA). The mean arterial pressure (MAP), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were recorded.

**Assessment of antioxidant capacity and oxidative stress**

The placental tissue was homogenised in 0.1 M phosphate buffer and centrifuged. Supernatants were collected and analysed for antioxidants and oxidative stress markers. Protein concentrations were determined using the Bio-Rad bicinchoninic acid (BCA) assay kit (Bio-Rad, Hercules, CA, USA).

- **Antioxidant capacity:** The antioxidant capacity of the placental tissue was measured using the Trolox equivalent antioxidant capacity (TEAC) assay kit (Cayman Chemical Company, Ann Arbor, MI, USA), in accordance with the manufacturer’s instructions.

- **Measurement of thiobarbituric acid reactive substances (TBARS):** TBARS are oxidative stress markers that bind to malo-
ndialdehyde. TBARS levels in placental tissue were determined using the TBARS assay kit (Cayman Chemical Company) in accordance with the manufacturer’s instructions.

**Protein carbonyl measurement:** The levels of oxidised proteins in tissue can be used as an indicator of oxidative stress. Protein carbonyl levels in the placental lysates were measured using the protein carbonyl colorimetric assay kit (Cayman Chemical Company). Protein carbonyls react with 2,4-dinitrophenylhydrazine to form a Schiff base that produces hydrazone, which is measured using a spectrophotometer set to quantify absorption at 385 nm.

**Catalase activity:** The activity of the antioxidant enzyme catalase was measured in placental tissue using a commercial assay kit (Cayman Chemical Company) in accordance with the manufacturer’s instructions. The data were recorded as U/mg of tissue protein.

**Placental nitric oxide (NO)**

Levels of NO in the peritoneal fluid were quantified using the nitrate/nitrite colorimetric assay kit (Cayman Chemical Company). This involves the conversion of nitrate to nitrite by nitrate reductase. The addition of Griess reagents then converts the nitrite to a deep-purple coloured azo compound, which is measured using an ELISA reader set to quantify absorption at 540 nm. The quantity of the azo compound accurately reflects the nitrite concentration of the original sample.

**Reverse transcription polymerase chain reaction (RT-PCR) analysis**

Total RNA was isolated from placental tissues and quantified using a BioPhotometer (Eppendorf, Hamburg, Germany) for RT-PCR analysis. First strand cDNA was synthesised using a cDNA reverse transcription kit (Applied Biosystems, Inc., Foster City, CA, USA). PCR was performed using a 7300 Real-Time PCR System (Applied Biosystems, Inc.) with SYBR green fluorescence. The following primers were used for amplification: VEGF-sense, 5’–ACCATGAACTTTCTGCTC–3’; VEGF-antisense, 5’–GGACGGCTTGAAGATATA–3’; VEGFR-1/Flt-1-sense, 5’–TTTGCATAGCTTCCAATAAGTTG–3’; VEGFR-1/Flt-1-antisense, 5’–CATGACAGTCTAAAGTGGTGGAAC–3’; GAPDH-sense, 5’–CACCACCATGGAGAAGGC–3’, GAPDH-antisense, 5’–CCATCCACAGTCTTCTGA–3’. The PCR products were separated using 2% agarose gel electrophoresis. The bands were stained with 0.05% ethidium bromide and their intensities quantified using a Bio Gel imaging system (Bio Rad).

**Immunoblotting**

The placental tissues were homogenised on ice in radio-immune precipitation assay (RIPA) lysis buffer containing 50 mM Tris-HCl (pH 7.6), 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS), phenylmethylsulphonyl fluoride (PMSF), 1 mg/L aprotinin and 1 mg/L leupeptin. The samples were centrifuged and the protein concentrations of the superna-

![Fig. 1. Punicalagin decreased systolic (a) and diastolic (b) blood pressure and also decreased mean arterial pressure (c). Values are expressed as means±standard deviation (SD), n=6; one-way analysis of variance (ANOVA) followed by Duncan’s multiple range test (DMRT) showed p<0.05; *p<0.05 vs. control; the letters a–e indicate mean values from experimental groups that differ significantly, p<0.05.](image-url)
tants determined using the BCA assay kit (Bio-Rad). Equivalent quantities of protein (50 μg) from each group were separated using 10% SDS-polyacrylamide gel electrophoresis (PAGE). The separated protein bands were transferred to polyvinylidene difluoride (PVDF) membranes (Invitrogen, Carlsbad, CA, USA) and blocked for 60 min at 37°C using Tris buffered saline with Tween-20 (TBST) buffer (20 mM Tris pH 7.6, 137 mM NaCl and 0.1% Tween 20) with 5% non-fat milk. The membranes were incubated overnight at 4°C with specific primary antibodies (1:1,000) and then washed with TBST three times. Finally, the membranes were incubated at 37°C for 60 min with HRP-labelled secondary antibodies (1:2,000). The positive bands were detected using an enhanced chemiluminescence detection kit (Merck Millipore, Burlington, MA, USA) and analysed using a ChemiDoc XRS imaging system (Bio-Rad). β-Actin was used as an internal control to normalise protein concentrations.

**Statistical analysis**

The experimental data were analysed using SPSS software (ver. 21.0; SPSS, Inc., Chicago, IL, USA). Group evaluations were performed using one-way analysis of variance (ANOVA) and Duncan’s multiple range test (DMRT). A p-value<0.05 was considered statistically significant.

**RESULTS**

**Effect of punicalagin on blood pressure**

Pregnant female rats that were treated with L-NAME had elevated SBP and DBP from day 14 through until day 20 (Figs. 1a-c). The mean SBP of L-NAME-treated rats was 172.6±2.32 mmHg on day 14 and 169.7±1.38 mmHg on day 20. These values were significantly higher than those recorded for the other experi-

![Fig. 2. Punicalagin increased placental nitric oxide (NO) levels.](image)

Values are expressed as means±SD, n=6; one-way ANOVA followed by DMRT showed p<0.05; *p<0.05 vs. control; **p<0.05 vs. NG-nitro-L-arginine methyl ester (L-NAME); the letters a–e indicate mean values from experimental groups that differ significantly, p<0.05.

![Fig. 3. Punicalagin enhanced the antioxidant capacity of the placenta (a), Punicalagin decreased the level of thiobarbituric acid reactive substances (TBARS) (b) and also decreased protein carbonyl levels in the placenta (c) and restored normal catalase activity levels (d).](image)

Values are expressed as means±SD, n=6; one-way ANOVA followed by DMRT showed p<0.05; *p<0.05 vs. control; **p<0.05 vs. L-NAME; the letters a–e indicate mean values from experimental groups that differ significantly, p<0.05.
mental groups (p<0.05). The MAP measurements were similar to those recorded for SBP and DBP. The control group animals that were not treated with L-NAME had consistent BP measurements throughout the entire gestation period with only insignificant changes. The SBP and DBP measurements recorded for punicalagin-treated animals were significantly lower than those recorded for the L-NAME-alone group (p<0.05). Punicalagin-treated rats had significantly lower MAPs compared with the L-NAME-treated group from day 14 through until day 20. The highest dose of punicalagin (100 mg) decreased BP more effectively than did the lower doses of 25 and 50 mg.

Punicalagin enhanced nitric oxide levels

The levels of vasodialator, NO in the placental tissues were measured. Placental NO concentrations were observed to be significantly (p<0.05) decreased in the L-NAME compared with the control-animal group (p<0.05; Fig. 2). Treatment with punicalagin at 25, 50 or 100 mg/kg resulted in dose-dependent increases in NO levels (p<0.05). 100 mg dose of punicalagin was found to be more effective compared to 25 or 50 mg doses. The NO levels observed in rats given the 100 mg-punicalagin dose were found to be near normal control group levels, indicating the efficacy of punicalagin.

Punicalagin reduced oxidative stress

Compared with the control group, the L-NAME-alone rats had a significantly decreased placental antioxidant capacity and significantly increased levels of TBARS and protein carbonyls (p<0.05; Figs. 3a-d). Additionally, the activity of the antioxidant enzyme catalase in the placental tissue had increased to a level comparable with the TBARS. Punicalagin administration considerably improved the TEAC, and decreased the levels of TBARS and protein carbonyls. Catalase activity decreased to almost normal levels following punicalagin treatment. These observations suggest that punicalagin reduced L-NAME-induced oxidative stress.

Effects of punicalagin on PIH-related angiogenic imbalance

Angiogenic imbalance is strongly associated with the aetiology of hypertension and PE [35]. Administration of L-NAME to pregnant rats significantly decreased the expression of VEGF, both at the gene and protein levels (p<0.05). RT-PCR analysis revealed a marked decrease in VEGF mRNA levels in L-NAME-treated rats compared with the control group (Figs. 4a, b). The onset of PIH following L-NAME administration resulted in substantial increases in placental VEGFR-1/Flt-1 levels in the L-NAME-alone-treated rats compared with the control group.

Supplementation with 25, 50 or 100 mg/kg punicalagin caused a marked increase in VEGF mRNA levels and significantly decreased the levels of Flt-1 mRNA (p<0.05). The western blotting analyses also revealed significantly downregulated expression of VEGFR-1/Flt-1 and enhanced VEGF expression in response to treatment with punicalagin (Figs. 5a, b). These observations suggest that punicalagin effectively restored angiogenic balance.

DISCUSSION

PE is a hypertensive multisystem disorder and a principal cause of maternal and foetal mortality and morbidity [36] that affects 3-5% of pregnancies [37]. Although the pathophysiology of PE is not completely understood, the condition is generally associated with an abnormal placenta [1,2]. In this study, we investigated the effects of punicalagin in an L-NAME-induced animal model of PE. In humans, PE generally occurs during the third trimester, after 20 weeks of pregnancy, and our study was designed to reflect this. The gestation period of Sprague-Dawley rats is approximately 21 days; therefore, L-NAME was first administered on day 14.

L-NAME is an analogue of L-arginine. It competes at the ac-
Fig. 5. Punicalagin restored angiogenic balance. Western blotting analysis (a) and protein expression (b) revealed a marked decrease in VEGF levels in response to punicalagin treatment compared with control groups: L1, control; L2, L-NAME; L3, L-NAME+punicalagin (25 mg/kg); L4, L-NAME+punicalagin (50 mg/kg); L5, L-NAME+punicalagin (100 mg/kg). Values are expressed as means±SD, n=6; one-way ANOVA followed by DMRT showed p<0.05. Relative expression of proteins where the control expression level is set as 100%; *p<0.05 vs. control; †p<0.05 vs. L-NAME; the letters a-e indicate mean values from experimental groups that differ significantly, p<0.05.

Oxidative stress plays a critical role in the pathophysiology of PE [49]. The data reveal an increase in oxidative stress in patients with PE, as well as in animal models of PE [50-55]. Increases in the levels of free radicals produce oxidative damage in biomolecules, leading to cellular and endothelial dysfunction [56]. In this study, treatment with L-NAME resulted in elevated levels of placental malondialdehyde. The increased protein carbonyl content and decreased TEAC values reflected an increase in oxidative stress. Enhanced levels of placental catalase were also observed; this could be a protective measure to combat the excess of free radicals. Punicalagin decreased the level of placental oxidative stress, as reflected in the decreased levels of TBARS and protein carbonyls. This enhanced the total antioxidant capacity of the placenta and catalase activity was restored to levels similar to those measured in the control group.

Supplementation with antioxidants and essential fatty acids in pre-eclamptic women caused decreased oxidative stress and also aided in prevention or delayed onset of preeclampsia and as well improved the health of pregnant women [57,58]. Studies in rodent model of PE showed that ω-3 PUFA supplementation reduced placental oxidative stress and enhanced fetal growth [59]. Studies demonstrated that supplementation with standard antioxidants-vitamin C and E markedly reduced oxidative stress and endothelial dysfunction [60] and pre-eclampsia [61]. The antioxidant efficacy of punicalagin could be responsible for reducing oxidative stress and improving TEAC.

Several studies have investigated the relationship between PE and altered placental vascular development [62-64]. The signal protein VEGF is involved in both vasculogenesis and angiogenesis, which are critical for the development of the placenta [65,66]. Angiogenic imbalance is frequently associated with PE [67,68]. In patients with PE, the altered levels of VEGF and its receptors (VEGFR-1/Flt-1) disrupt angiogenesis, causing endothelial dysfunction and placental abnormalities [69,70]. In our study, the significant decreases in VEGF expression and enhanced levels of Flt-1 that we observed following treatment with L-NAME showed that the angiogenic balance had been altered under hypertensive conditions. Downregulated expression of VEGF was observed at both the gene and protein levels. Punicalagin markedly upregulated VEGF expression and suppressed VEGFR-1/Flt-1, restoring the angiogenic balance. Previous data demonstrated that resveratrol reduced soluble form of Flt-1 (sFlt-1) secretion from placenta that offers therapeutic potential in preeclampsia [71].

Several PE studies have reported decreases in blood pressure following restoration of angiogenic balance [15,23]. Therefore, restoring angiogenic balance probably contributed to the decreases in blood pressure that we observed. These findings suggest that punicalagin can reduce hypertension by restoring angiogenic balance. Both the increases in NO levels and restoration of angiogenic balance could have contributed to the observed decreases in blood pressure.
Effect of punicalagin in pregnancy induced hypertension

CONCLUSION

This study demonstrates that punicalagin can enhance NO levels, reduce oxidative stress and regulate the expression of VEGF and Flt-1, thereby reducing blood pressure in PIH. Punicalagin could potentially be used to treat PIH and PE. However, further studies will be required to comprehend the underlying molecular mechanisms involved.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Roberts JM, Escudero C. The placenta in preeclampsia. Pregnancy Hypertens. 2012;2:272-83.
2. Henao DE, Saleem MA. Proteinuria in preeclampsia from a podocyte injury perspective. Curr Hypertens Rep. 2013;15:600-605.
3. August P, Lindheimer M. Pathophysiology of preeclampsia. In: Laragh J, Brenner BM, editors. Hypertension. New York: Raven Press; 1995. p.2407-2426.
4. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005; 365:785-799.
5. Bijvank SW, Visser W, Duvekot JJ, Steegers EA, Edens MA, Rooft-hooft DW, Vulto AG, Hanff LM. Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;189:106-111.
6. Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy. 2003;22:203-212.
7. Backes CH, Markham K, Moorehead P, Cordero L, Nankervis CA, Giannone PJ. Maternal preeclampsia and neonatal outcomes. J Pregnancy. 2011;2011:214365.
8. Hamilton BE, Martin JA, Osterman MJ, Curtin SC, Matthews TJ. Births: final data for 2014. Natl Vital Stat Rep. 2015;64:1-64.
9. Jido TA, Yakasai IA. Preeclampsia: a review of the evidence. Ann Afr Med. 2013;12:75-85.
10. Burton GJ, Jauniaux E. Oxidative stress. Best Pract Res Clin Obstet Gynaecol. 2011;25:287-299.
11. Bhale DV, Hivre MD, Mahat RK, Bujurge AA. Comparative study of serum malondialdeyde levels as marker of oxidative stress in patients of pregnancy-induced hypertension and controls. J Med Sci. 2014;1:53-55.
12. Sutherland MR, Bertagnolli M, Lukaszewski MA, Huyard F, Zydorczyk C, Luu TM, Nuyt AM. Preterm birth and hypertension risk: the oxidative stress paradigm. Hypertension. 2014;63:12-18.
13. de Lucca L, Gallerreta FMP, de Lima Gonçalves T. Oxidative stress markers in pregnant women with preeclampsia. Am J Med Biol Res. 2015;3:68-73.
14. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658.
15. Gilbert JS, Verzwyvelt J, Colson D, Arany M, Karumanchi SA, Granger JP. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalsclerosis-induced hypertension. Hypertension. 2010;55:380-385.
16. Ohkuchi A, Hirashima C, Matsubara S, Takahashi K, Matsuda Y, Suzuki M. Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia. Hypertension. 2011;58:859-866.
17. Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R, Waugh R, McKenzie P, Kirwan P, Hennessy A. Uteroplacental ischemia results in proteinuric hypertension and elevated sFlt-1. Kidney Int. 2007;71:977-984.
18. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension. 2007;50:1142-1147.
19. Wang Y, Walsh SW. Antioxidant activities and mRNA expression of superoxide dismutase, catalase, and glutathione peroxidase in normal and preeclamptic placentas. J Soc Gynecol Investig. 1996;3:179-184.
20. Sedeek MH, Wang Y, Granger JP. Increased oxidative stress in a rat model of preeclampsia. Am J Hypertens. 2004;17:142A.
21. Bridges JP, Gilbert JS, Colson D, Gilbert SA, Dukes MP, Ryan MJ, Granger JP. Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertens. 2009;22:564-568.
22. Maynard SE, Venkatesha S, Thadhanri N, Karumanchi SA. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res. 2005;57:1R-7R.
23. Gilbert JS, Banek CT, Bauer AJ, Ginery A, Needham K. Exercise training attenuates placental ischemia-induced hypertension and angiogenic imbalance in the rat. Hypertension. 2012;60:1545-1551.
24. Arun N, Singh DP. Punica granatum: a review on pharmacological and therapeutic properties. Int J Pharma Sci Res. 2012;3:1240-1245.
25. Das S, Barman S. Antidiabetic and antihyperlipidemic effects of ethnolic extract of leaves of Punica granatum in alloxan-induced non-insulin-dependent diabetes mellitus albino rats. Indian J Pharmacol. 2012;44:219-224.
26. Viswanatha GL, Venkataramanganna MV, Prasad NB, Ashok G. Evaluation of anti-epileptic activity of leaf extracts of Punica granatum on experimental models of epilepsy in mice. J Intercult Ethnopharmacol. 2016;5:415-421.
27. Dikmen M, Ozurtok N, Ozurtok Y. The antioxidant potency of Punica granatum L. Fruit peel reduces cell proliferation and induces apoptosis on breast cancer. J Med Food. 2011;14:1638-1646.
28. Sineh Sepehr K, Baradaran B, Mazandarani M, Khori V, Shahneh EZ. Studies on the cytotoxic activities of punica granatum L. var. spinosa (Apple Punice) extract on prostate cell line by induction of apoptosis. ISRN Pharm. 2012;2012:547942.
29. Chen B, Longtine MS, Nelson DM. Punicalagin, a polyphenol in pomegranate juice, downregulates p53 and attenuates hypoxia-induced apoptosis in cultured human placental syncytiotrophoblasts.
Am J Physiol Endocrinol Metab. 2013;305:E1274-1280.

30. de Nigris F, Williams-Ignarro S, Botti C, Sica V, Ignarro LJ, Napoli C. Pomegranate juice reduces oxidized low-density lipoprotein down-regulation of endothelial nitric oxide synthase in human coronary endothelial cells. Nitric Oxide. 2006;15:259-263.

31. BenSaad LA, Kim KH, Quah CC, Kim WR, Shahimi M. Anti-inflammatory potential of elagic acid, gallic acid and punicalagin A&B isolated from Punica granatum. BMC Complement Altern Med. 2017;17:47.

32. National Research Council (U.S.), Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research. Guide for the care and use of laboratory animals. 8th ed. Washington, D.C.: National Academy Press; 2011.

33. Kemse NG, Kale AA, Joshi SR. A combined supplementation of omega-3 fatty acids and micronutrients (folic acid, vitamin B12) reduces oxidative stress markers in a rat model of pregnancy induced hypertension. PLoS One. 2014;9:e11992.

34. Kemse NG, Kale AA, Joshi SR. Supplementation of maternal omega-3 fatty acids to pregnancy induced hypertension Wistar rats improves IL10 and VEGF levels. Prostaglandins Leukot Essent Fatty Acids. 2016;104:25-32.

35. Banek CT, Bauer AJ, Gingery A, Gilbert JS. Timing of ischemic insult alters fetal growth trajectory, maternal angiogenic balance, and markers of renal oxidative stress in the pregnant rat. Am J Physiol Regul Integr Comp Physiol. 2012;303:R658-664.

36. Galbiati S, Inversetti A, Causarano V, Stenirri S, Soriani N, Ambrosi A, Valsecchi L, Candiani M, Cremonesi L, Ferrari M, Smid M. HIF1A and MIF as potential predictive mRNA biomarkers of pre-eclampsia: a longitudinal prospective study in high risk population. Clin Chem Lab Med. 2015;53:1339-1347.

37. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 1993;341:1447-1451.

38. Anggård E. Nitric oxide: mediator, murderer, and medicine. Lancet. 1994;343:1199-1206.

39. Molnár M, Hertelendy F. Omega-nitro-L-arginine, an inhibitor of nitric oxide synthesis, increases blood pressure in rats and reverses the pregnancy-induced refractoriness to vasopressor agents. Am J Obstet Gynecol. 1992;166:1560-1567.

40. Yallampalli C, Garfield RE. Inhibition of nitric oxide synthesis in rats during pregnancy produces signs similar to those of preeclampsia. Am J Obstet Gynecol. 1993;169:1316-1320.

41. Vallance P, Chan N. Endothelial function and nitric oxide: clinical relevance. Heart. 2001;85:342-350.

42. Conrad KP, Joffe GM, Kruzszya H, Kruzszya R, Rochelle LG, Smith RP, Chavez JE, Mosher MD. Identification of increased nitric oxide biosynthesis during pregnancy in rats. FASEB J. 1993;7:566-571.

43. Choi JW, Im MW, Pai SH. Nitric oxide production increases during normal pregnancy and decreases in preeclampsia. Ann Clin Lab Sci. 2002;32:257-263.

44. Seligman SP, Buyon JP, Clancy RM, Young BK, Abramson SB. The role of nitric oxide in the pathogenesis of preeclampsia. Am J Obstet Gynecol. 1994;171:944-948.

45. Poudel R, Stanley JL, Rueda-Clausen CF, Andersson IJ, Sibley CP, Davidge ST, Baker PN. Effects of resveratrol in pregnancy using murine models with reduced blood supply to the uterus. PLoS One. 2013;8:e64401.

46. Vega CC, Reyes-Castro LA, Rodríguez-González GL, Bautista CJ, Vázquez-Martínez M, Larrea F, Chamorro-Cevallos GA, Nathanielz PW, Zambrano E. Resveratrol partially prevents oxidative stress and metabolic dysfunction in pregnant rats fed a low protein diet and their offspring. J Physiol. 2016;594:1483-1499.

47. Xiao S, Zhang M, Liang Y, Wang D. Celastrol synergizes with oral nifedipine to attenuate hypertension in preeclampsia: a randomized, placebo-controlled, and double blinded trial. J Am Soc Hypertens. 2017;11:598-603.

48. Shi DD, Guo JJ, Zhou L, Wang N. Epigallocatechin gallate enhances treatment efficacy of oral nifedipine against pregnancy-induced severe pre-eclampsia: a double-blind, randomized and placebo-controlled clinical study. J Clin Pharm Ther. 2018;43:21-25.

49. Draganovic D, Lucic N, Jovicic J. Oxidative stress marker and pregnancy induced hypertension. Med Arch. 2016;70:437-440.

50. Tanir HM, Sener T, Inal M, Akyuz F, Uzuner K, Sirvi E. Effect of quercetine and glutathione on the level of superoxide dismutase, catalase, malonyldialdehyde, blood pressure and neonatal outcome in a rat model of pre-eclampsia induced by NG-nitro-L-arginine-methyl ester. Eur J Obstet Gynecol Reprod Biol. 2005;118:190-195.

51. Mehendale S, Kilari A, Danang K, Taralekar V, Mahadik S, Joshi S. Fatty acids, antioxidants, and oxidative stress in pre-eclampsia. Int J Gynaecol Obstet. 2008;100:234-238.

52. Gohil JT, Patel PK, Gupta P. Evaluation of oxidative stress and antioxidant defence in subjects of preeclampsia. J Obstet Gynaecol India. 2011;61:638-640.

53. Yang X, Guo L, Sun X, Chen X, Tong X. Protective effects of hydro-gen-rich saline in preeclampsia rat model. Placenta. 2011;32:681-686.

54. Kulkarni A, Mehendale S, Pisl H, Kilari A, Danang K, Salunkhe S, Taralekar V, Joshi S. Association of omega-3 fatty acids and homocysteine concentrations in pre-eclampsia. Clin Nutr. 2011;30:60-64.

55. Pimentel AM, Pereira NR, Costa CA, Mann GE, Cordeiro VS, de Moura RS, Brunini TM, Mendes-Ribeiro AC, Resende AC. L-arginine-nitric oxide pathway and oxidative stress in plasma and platelets of patients with pre-eclampsia. Hypertens Res. 2013;36:783-788.

56. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160:1-40.

57. Hopkins MH, Fedirko V, Jones DP, Perry PD, Bostick RM. Antioxidant micronutrients and biomarkers of oxidative stress and inflammation in colorectal adenoma patients: results from a randomized, controlled clinical trial. Cancer Epidemiol Biomarkers Prev. 2010;19:850-858.

58. Jones ML, Mark PJ, Waddell BJ. Maternal dietary omega-3 fatty acids and placental function. Reproduction. 2014;147:R143-152.

59. Jones ML, Mark PJ, Mori TA, Keenan JA, Waddell BJ. Maternal dietary omega-3 fatty acid supplementation reduces placental oxidative stress and increases fetal and placental growth in the rat. Biol Reprod. 2013;88:37.

60. Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt BJ, Parmar K, Bewley SJ, Shennan AH, Steer PJ, Poston L. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet. 1999;354:810-816.

61. Chappell LC, Seed PT, Kelly FJ, Briley A, Hunt BJ, Charnock-Jones DS, Mallet A, Poston L. Vitamin C and E supplementation in women at risk of preeclampsia is associated with changes in indices
of oxidative stress and placental function. *Am J Obstet Gynecol.* 2002;187:777-784.

62. Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. *Semin Nephrol.* 2011;31:33-46.

63. Verlohren S, Stepan H, Dechend R. Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. *Clin Sci (Lond).* 2012;122:43-52.

64. Llurba E, Crispi F, Verlohren S. Update on the pathophysiological implications and clinical role of angiogenic factors in pregnancy. *Fetal Diagn Ther.* 2015;37:81-92.

65. Pavlov N, Frenod JL, Guibourdenche J, Degrelle SA, Evain-Brion D, Badet J. Angiogenin expression during early human placental development; association with blood vessel formation. *Biomed Res Int.* 2014;2014:781632.

66. Santos TC, Oliveira MF, Papa PC, Dantzer V, Miglino MA. VEGF system expression by immunohistochemistry and real-time RT-PCR study on collared peccary placenta. *Theriogenology.* 2014;82:834-843.

67. Anderson CM, Ralph JL, Ohm JE. Differential DNA methylation in placental and maternal angiogenic genes is not altered in preeclampsia. *Pregnancy Hypertension.* 2015;5:45-46.

68. Sahay AS, Sundrani DP, Wagh GN, Mehandale SS, Joshi SR. Regional differences in the placental levels of oxidative stress markers in pre-eclampsia. *Int J Gynaecol Obstet.* 2015;129:213-218.

69. Sundrani DP, Reddy US, Joshi AA, Mehandale SS, Chavan-Gautam PM, Hardikar AA, Chandak GR, Joshi SR. Differential placental methylation and expression of VEGF, FLT-1 and KDR genes in human term and preterm preeclampsia. *Clin Epigenetics.* 2013;5:6.

70. Sahay AS, Patil VV, Sundrani DP, Joshi AA, Wagh GN, Gupte SA, Joshi SR. A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia. *Hypertens Res.* 2014;37:753-758.

71. Cudmore MJ, Ramma W, Cai M, Fujisawa T, Ahmad S, Al-Ani B, Ahmed A. Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta. *Am J Obstet Gynecol.* 2012;206:253.e10-15.